TFFP: חוב לטווח קצר של החברה TFF Pharmaceuticals

TFF Pharmaceuticals generates revenue by licensing its inhalation powder creation method, utilizing an advantageous asset-light model that avoids capital expenditures on manufacturing plants. The business is centered on a thin-film freezing platform that enables partners to implement unique drug delivery methods to the lungs. This chart captures the specific short-term debt metric at 0.00. Additionally, TFF Pharmaceuticals is implementing automated laboratory systems to eliminate human error during drug formulation.

Amidst the liquidation of TFF Pharmaceuticals (TFFP) due to a capital deficit, the analysis of liabilities maturing within one year becomes a critical tool for assessing residual resources. The short-term debt time series reflects liquidity dynamics and the risk of cash flow gaps, allowing investors to determine the issuer's actual financial resilience through the monitoring of current borrowings prior to the official publication of financial statements.